lncRNA DGCR5在非小细胞肺癌组织中的表达及其与临床病理特征的相关性分析

摘要 目的：探究lncRNA DGCR5在非小细胞肺癌(NSCLC)组织中的表达及其与临床病理特征的相关性。方法：选取2020年1月至2021年12月在我院肿瘤科收治的进行手术治疗的NSCLC患者86例，在手术期间从患者获得肿瘤和非肿瘤的肺癌旁组织样本。采用qRT-PCR测定肿瘤组织及癌旁组织中lncRNA DGCR5表达水平。分析lncRNA DGCR5表达水平与NSCLC患者性别、年龄、临床分期、T分期、N分期等临床病理参数的关系，lncRNA DGCR5表达水平与患者预后总生存期（OS）和无进展生存期（PFS）的关系。结果：与癌旁组织相比，lncRNA DGCR5在NSCLC肿瘤组织中的表达水平相对较低，差异具有统计学意义（P<0.01）。lncRNA DGCR5表达与肿瘤分化程度、TNM分期、肿瘤体积、淋巴转移和远处转移之间存在明显相关性，差异具有统计学意义（P<0.05）。采用Kaplan-Meier法进行生存分析，研究发现lncRNA DGCR5高表达组中位OS及中位DFS分别显著高于lncRNA DGCR5低表达组（P<0.05）。低分化程度、II+ IIIa临床分期、N1-N3淋巴转移、远处转移、及lncRNA DGCR5 低表达均与NSCLC患者总生存率和无进展生存率相关。结论：LncRNA DGCR5在NSCLC患者肿瘤组织中的表达量降低，NSCLC患者血LncRNA DGCR5表达水平与分化程度、TNM分期、淋巴转移、远处转移及预后具有相关性。LncRNA DGCR5可作为早期诊断和治疗NSCLC的新型生物标志物。

Expression of lncRNA DGCR5 in non-small Cell Lung Cancer and its Correlation with Clinicopathological Characteristics

ABSTRACT Objective: To investigate the expression of lncRNA DGCR5 in non-small cell lung cancer (NSCLC) and its correlation with clinicopathological features. Methods: 86 patients with NSCLC who were treated surgically in the oncology department of our hospital from January 2020 to December 2021 were selected, and tumor and non tumor lung cancer tissue samples were obtained from the patients during the operation. The expression level of lncRNA DGCR5 in tumor tissues and adjacent tissues was determined by qRT PCR. To analyze the relationship between the expression level of lncRNA DGCR5 and the clinicopathological parameters of NSCLC patients, such as gender, age, clinical stage, T stage, N stage, etc. The relationship between the expression level of lncRNA DGCR5 and the prognosis of patients with total survival (OS) and progression free survival (PFS). Results: Compared with the adjacent tissues, the expression level of lncRNA DGCR5 in NSCLC tumor tissues was relatively low, and the difference was statistically significant (P<0.01). The expression of lncRNA DGCR5 was significantly correlated with tumor differentiation, TNM stage, tumor volume, lymphatic metastasis and distant metastasis (P<0.05). Kaplan Meier method was used for survival analysis. It was found that the median OS and DFS in the high expression group of lncRNA DGCR5 were significantly higher than those in the low expression group of lncRNA DGCR5 (P<0.05). Low differentiation, clinical stage of II+IIIa, N1-N3 lymphatic metastasis, distant metastasis, and low expression of lncRNA DGCR5 were all related to the overall survival rate and progression free survival rate of NSCLC patients. Conclusion: The expression of LncRNA DGCR5 in tumor tissues of NSCLC patients is decreased. The expression level of LncRNA DGCR5 in blood of NSCLC patients is correlated with the degree of differentiation, TNM stage, lymphatic metastasis, distant metastasis and prognosis. LncRNA DGCR5 can be used as a new biomarker for early diagnosis and treatment of NSCLC.